Lixte Biotechnology Holdings, Inc.
LIXT
$3.46
$0.1655.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 16.04% | 6.36% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.61% | 15.22% | |||
| Operating Income | -9.61% | -15.22% | |||
| Income Before Tax | -9.32% | -14.88% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.32% | -14.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.32% | -14.88% | |||
| EBIT | -9.61% | -15.22% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 0.70% | -4.55% | |||
| Normalized Basic EPS | 0.67% | -4.55% | |||
| EPS Diluted | 0.70% | -4.55% | |||
| Normalized Diluted EPS | 0.67% | -4.55% | |||
| Average Basic Shares Outstanding | 10.07% | 9.88% | |||
| Average Diluted Shares Outstanding | 10.07% | 9.88% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||